Cargando…

Novel Use of N-Acetylcysteine in Management of Tyrosine Kinase Inhibitor Induced Acute Liver Injury

Tyrosine kinase inhibitors (TKIs) have been adopted in the treatment of a variety of malignancies. Despite their popularity, the underlying mechanism of the adverse effects seen with the use of TKIs is not completely understood. Acute liver injury is a known side effect of many of these drugs. Some...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Tarang, Tarun, Tushar, Hudhud, Dania, Krvavac, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935342/ https://www.ncbi.nlm.nih.gov/pubmed/31890447 http://dx.doi.org/10.7759/cureus.6251

Ejemplares similares

Diffuse Alveolar Hemorrhage: An Uncommon Manifestation of Vaping-associated Lung Injury
por: Wilhite, Rodger, et al.
Publicado: (2019)

The case of a 72-Year-Old Male with Hematemesis and Pneumomediastinum due to Acute Bacterial Esophageal Necrosis
por: Karle, Ethan, et al.
Publicado: (2019)

Avoiding Unnecessary Repeat Laboratory Testing
por: Patel, Tarang, et al.
Publicado: (2019)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023)

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma
por: Khan, Muhammad, et al.
Publicado: (2020)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors
por: Liu, Jiayin, et al.
Publicado: (2023)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
por: Mou, Lisha, et al.
Publicado: (2021)

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
por: Abbas, Hussein A., et al.
Publicado: (2021)

Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
por: Feng, Yiyi, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
por: Liu, Hongyan, et al.
Publicado: (2021)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
por: Zhang, Ninggang, et al.
Publicado: (2022)

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
por: Shi, Binhao, et al.
Publicado: (2023)

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
por: Vasilogianni, Areti-Maria, et al.
Publicado: (2023)

S-Nitroso-N-Acetylcysteine Ameliorates Ischemia-Reperfusion Injury In The Steatotic Liver
por: Andraus, Wellington, et al.
Publicado: (2010)

N-Acetylcysteine in the Management of Acute Liver Failure From Sickle Cell Hepatic Crisis
por: Zhang, Xiaojie, et al.
Publicado: (2019)

The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
por: Kalra, Anjali, et al.
Publicado: (2023)

Tyrosine kinases in nodal peripheral T-cell lymphomas
por: Piccaluga, Pier Paolo, et al.
Publicado: (2023)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook
por: Miles, Brittany, et al.
Publicado: (2021)

Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma
por: Tang, Tin-Yun, et al.
Publicado: (2021)

Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
por: Shen, Jing, et al.
Publicado: (2022)

The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
por: Abu-Tineh, Mohammad, et al.
Publicado: (2023)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review
por: Sanabria-Cabrera, Judith, et al.
Publicado: (2022)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Role of N-acetylcysteine in the management of COPD
por: Sadowska, Anna M, et al.
Publicado: (2006)

The role for N-acetylcysteine in the management of COPD
por: Dekhuijzen, PNR, et al.
Publicado: (2006)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients
por: Ma, Kaifang, et al.
Publicado: (2019)

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
por: Gerson-Gurwitz, Adina, et al.
Publicado: (2021)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_555up0crfgc9ourje0jtr7lf08